Improving ovarian cancer diagnosis in primary care
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is looking at how doctors can better use the CA125 blood test to find ovarian cancer earlier. If you are being tested for ovarian cancer in primary care, this study might help improve how future patients are diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman being checked by your primary care doctor (GP) for possible ovarian cancer.
- You have had a blood test called CA125 (a common test for ovarian cancer) as part of your regular care.
- You do not have symptoms that could be ovarian cancer but weren't tested for it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
This trial tests a new blood test (OCS) that may help detect if ovarian cancer comes back after initial treatment. It is for people whose CA125 levels were normal at diagnosis.
This study is testing a new blood test to help find ovarian cancer early in women who are at average risk. By joining, you may help improve early detection, which could lead to better outcomes.
This trial studies whether a simple blood test (liquid biopsy) can help tell if an ovarian mass is cancer or not, and if it can catch cancer early. If you're going to have surgery for a suspicious ovarian mass, this test might give extra information to guide your care.
This study is testing new blood tests that might help detect ovarian cancer earlier by looking for specific markers. It involves people with suspected ovarian cancer and healthy volunteers, and aims to improve how we diagnose the disease.
This study is testing a new blood test (called the EARLY panel) to see how well it can detect ovarian cancer in postmenopausal women aged 50–74. It aims to find out if the test is accurate and practical for routine screening.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.